AU2014282942A1

AU2014282942A1 - Compositions comprising at least one polymethoxyflavone, flavonoid, liminoid, and/or tocotrienol useful in combination therapies for treating diabetes

Info

Publication number: AU2014282942A1
Application number: AU2014282942A
Authority: AU
Inventors: Najla Guthrie
Original assignee: KGK Synergize Inc
Current assignee: 1242753 Ontario Inc
Priority date: 2013-06-17
Filing date: 2014-06-13
Publication date: 2016-01-07
Anticipated expiration: 2034-06-13
Also published as: US20140371303A1; NZ754507A; WO2014203059A1; AU2014282942B2; CA2915751A1; EP3010499A4; AU2019200898B2; US9132117B2; NZ715160A; AU2019200898A1; US9610276B2; EP3010499A1; US20150328184A1

Abstract

Compositions comprising select natural products have been found to be useful as supplements to known medicaments for treating elevated blood glucose, HbAlc, blood pressure and cholesterol levels in persons suffering from metabolic syndrome, insulin resistance, and type 2 diabetes. The natural products of interest include polymethoxyflavones, flavonoids, liminoids, and tocotrienols, while the known medicaments include metformin. In preferred embodiments, the natural products are polymethoxyflavones found in citrus plants, such as nobiletin, tangeretin, and synephrin. Use of the natural product of interest will preferably result in HbAlc ≤ 7%, LDL-C ≤ 100 mg/dL, total cholesterol ≤ 200 mg/dL; and systolic blood pressure ≤ 130 mm Hg.

Description

WO 2014/203059 PCT/IB2014/001069 Compositions comprising at least one polymethoxyflavone, flavonoid, liminoid, and/or tocotrienol useful in combination therapies for treating diabetes FIELD OF THE INVENTION 5 The present invention relates to compositions and methods for glycemic control of subjects with impaired fasting glucose, and, more specifically, to compositions and methods for improving glycemic control in subjects currently using conventional therapies. BACKGROUND OF THE INVENTION 10 Metabolic syndrome, a condition thought to be caused by a combination of obesity, sedentary lifestyle, diet and genetics, has been found to increase the risk for cardiovascular disease and type 2 diabetes. The main characteristics of this syndrome are abdominal obesity, atherogenic dyslipidemia (elevated blood triglycerides, reduced HDL cholesterol), elevated blood pressure, insulin resistance (IR) (with or without glucose intolerance), prothrombotic 15 and proinflammatory states and endothelial dysfunction. During the past 20 years, metabolic syndrome has become highly prevalent in North America, currently affecting an estimated 50% of the population older than 60 years. Insulin resistance, one of the characteristics of metabolic syndrome, is defined as an impaired ability of insulin to stimulate glucose uptake and lipolysis and to modulate liver and muscle 20 lipid metabolism. In animals and humans, insulin resistance syndrome leads to compensatory hyperinsulinemia and to various defects in lipid metabolism such as enhanced secretion of atherogenic, triacylglycerol-rich very low-density lipoproteins (VLDL), increased liberation of nonesterified fatty acids (NEFA) from adipose tissue and increased accumulation of triacylglycerols in the liver. 25 Current therapies in prevention and treatment of type 2 diabetes include diet and drugs. Dietary strategies designed to diminish the risk of heart disease associated with insulin resistance syndrome and type 2 diabetes are currently not well established. The most common approach is the recommendation to lower intake of total calories, especially fat and sugar, and to increase intake of fibers. The typical pharmacologic approach to the treatment 30 of this disease focuses on drugs targeting obesity, glucose-lowering medications (e.g., metformin and acarbose) and more recently, insulin sensitizers such as PPAR-a and PPAR-y activators, fibrates and thiazolidienodiones (TZDs). Unfortunately, therapies involving existing drugs have limited efficacy or tolerability and show significant side effects. There WO 2014/203059 PCT/IB2014/001069 2 exists a need to provide a safe and effective method of treating metabolic syndrome and the diseases associated with it. In the United States alone, approximately 24 million people suffer from diabetes with approximately 1.3 million being diagnosed with the disease each year. An aging population, 5 rising obesity rates and an increasingly sedentary lifestyle have been attributed to the increase in incidence and prevalence. Furthermore, a rapid increase of type 2 diabetes in persons 30 39 years of age and in children and adolescents has been of special concern. Global prevalence rates are expected to increase from 6.4% and 285 million in 2010 to 7.7% and 439 million by 2030. 10 Clinical treatment goals for type 2 diabetes are directed towards lowering blood glucose levels to forestall diabetes related complications. More recently, the use of pharmacotherapies and their negative impact on cardiovascular risk have caused concern over available treatment modalities. An increased risk of myocardial ischemia has been identified with thiazolidinedione use, while earlier studies have linked Sulphonylureas to increased 15 cardiovascular risk. Of further concern have been the contrasting outcomes of the ACCORD study which reported that lowering blood glucose to normal levels was associated with increased mortality, but the ADVANCE study did not report such findings. Such controversies in the results may suggest that treatment strategies for type 2 diabetes are not fully understood. 20 This begs the question if improving glycemia is sufficient to provide clinical merit in the treatment algorithm for diabetes. Currently, several therapeutic strategies include metformin in the management algorithm for type 2 diabetes with mono, di and tri therapy needing to be added to the algorithm. Therapies involving existing pharmaceuticals have limited efficacy or tolerability and show significant side effects. Many of the side effects of pharmaceuticals 25 are thought to be associated with nutritional deficiencies caused by medications taken over a period of time ultimately resulting in a cascade of biochemical changes due to drug associated nutrient depletion. Unfortunately, long term treatment with metformin has been reported to cause vitamin B12 deficiencies. Despite the available treatment modalities, the risk of cardiovascular events has increased 2-4 fold in patients diagnosed with type 2 30 diabetes. As a patient's beta cell function declines, intensified treatment beyond the initial monotherapy regimen is required. The prevalence of obesity is also a concern in these patients and is thought to be a driver of cardiovascular events. The "State of Diabetes in America" report on diabetes management evaluated current management strategies and found that, despite advances in diabetes care, blood sugar levels WO 2014/203059 PCT/IB2014/001069 3 of millions of Americans were not controlled putting them at risk of diabetes related complications. It is possible that effective combination therapies that consist of pharmaceutical drugs and nutraceutical products may provide a new treatment algorithm that would be beneficial to diabetic patients who do not respond to drug therapy alone. 5 A 2005 report from the American Association of Clinical Endocrinologists (AACE) stated that 2 out of 3 Americans with type 2 diabetes did not achieve the AACE recommended blood sugar control goal of <6.5%. Nationally, an average of 67% of people with type 2 diabetes had blood sugar levels exceeding the AACE recommended goal. These numbers have a direct impact on cardiovascular disease risk factors for this population of subjects. 10 NHANES 1999-2000 reported that only 7.3% of all adults diagnosed with type 2 diabetes were within acceptable range for the cardiovascular disease risk factors of HbA 1 c, blood pressure and total cholesterol. The American Association of Clinical Endocrinologists (AACE) acknowledges the importance of nutritional medicine in medical practice and in their guidelines identifies "complementary" or "integrative nutritionals" as products that may be 15 used in combination with FDA approved therapies. Needs exist for compositions and methods that provide anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting ACCE and ADA recommended targets for blood glucose, HbA 1c, blood pressure and total cholesterol. 20 SUMMARY OF THE INVENTION It is therefore an object of the present invention to provide compositions and methods for glycemic control of subjects with impaired fasting glucose. The compositions and methods of the present invention may provide anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting ACCE and ADA recommended 25 targets for blood glucose, HbAlc, blood pressure and total cholesterol. Embodiments of the present invention may include methods for administering an effective amount of a composition to a subject diagnosed with diabetes where the subject is currently taking one or more prescribed medications for control of diabetes but are not within one or more guidelines including: HbAlc 7%; LDL-C 100 mg/dL; total cholesterol < 200 30 mg/dL; and systolic blood pressure < 130 mmHg. After a predetermined period of supplementation with the composition, the subject may be within at least one of the one or more guidelines. The composition may include at least one limonoid, at least one flavonoid and at least one tocotrienol. The composition may include at least one polymethoxyflavone. The one or more prescribed medications may be metformin. The subject may be a human.

WO 2014/203059 PCT/IB2014/001069 4 The predetermined period of supplementation may be at least 12 weeks and/or at least 24 weeks. Additional features, advantages, and embodiments of the invention are set forth or apparent from consideration of the following detailed description, drawings and claims. Moreover, it 5 is to be understood that both the foregoing summary of the invention and the following detailed description are exemplary and intended to provide further explanation without limiting the scope of the invention as claimed. BRIEF DESCRIPTION OF THE DRAWINGS 10 The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate preferred embodiments of the invention and together with the detailed description serve to explain the principles of the invention. In the drawings: Figs la - I d are graphs showing serum glucose concentrations over a 4-hour period following 15 a 1Og OGTT at baseline, week 12 and week 24 of supplementation with the composition of an embodiment of the present invention or placebo. Figs. 2a - 2b are graphs showing serum insulin concentrations over a 4-hour period following a 1OOg OGTT at baseline, week 12 and week 24 of supplementation with the composition of an embodiment of the present invention or placebo. 20 DETAILED DESCRIPTION OF THE INVENTION The present invention relates to the use of compositions including at least one of limocitrin derivative, quercetin derivative, polymethoxyflavone, tocotrienol and mixtures thereof alone or in combination with at least one glycemic control drug for the treatment of subjects with 25 impaired fasting glucose. Limocitrin derivatives are a group of citrus-derived flavonoids that are naturally occurring in the plant or are chemically synthesized. 5-desmethylsinesetin is chemically synthesized form of sinensetin. Sinensetin occurs in trace levels in mandarin orange leaves, and in orange and mandarin peel. Flavonoids are polyphenolic compounds that occur ubiquitously in foods of 30 plant origin. The major dietary sources of flavonoids are vegetables, fruits, and beverages such as tea and red wine. Flavonoids have been demonstrated to be the most potent dietary antioxidants and in light of the large dietary consumption, flavonoids make a major contribution to the antioxidant potential of the human diet. The main food sources of WO 2014/203059 PCT/IB2014/001069 5 flavonols and flavones are black tea, onions, apples, herbs, and spices such as cloves and black pepper. These compounds may include, but are not limited to, the following examples of limocitrin and quercetin derivatives: limocitrin-3,7,4'-trimethylether (5-hydroxy-3,7,8,3',4' 5 pentamethoxyflavone) limocitrin-3,5,7,4'-tetramethylether (3,5,7,8,3'4'-hexamethoxyflavone) limocitrin-3,5,7,4'-tetraethylether (8,3'-dimethoxy-3,5,7,4'-tetraethoxylfavone) limocitrin 3,7,4'-trimethylether-5-acetate quercetin tetramethylether (5-hydroxy-3,7,3',4' tetramethoxyflavone) quercetin 3,5-dimethylether-7,3'4'-tribenzyl ether quercetin pentamethylether (3,5,7,3',4'-pentamethoxyflavone) quercetin-5,7,3',4'-tetramethylether-3 10 acetate quercetin-5,7,3',4'-tetramethylether (3-hydroxy-5,7,3',4'-tetramethoxyflavone). Examples of naturally occurring polymethoxyflavones for the purposes of the present invention include, but are not limited to: 3,5,6,7,8,3',4'-heptamethoxflavone nobiletin (5,6,7,8,3',4'-hexamethoxyflavone) tangeretin (5,6,7,8,4'-pentametlioxyflavone) 5 desmethylnobiletin (5-hydroxy-6,7,8,3'4'-pentamethoxyflavone) tetra-O 15 methylisoscutellarein (5,7,8,4'-tetramethoxyflavone) 5-desmethylsinensetin (5-hydroxy 6,7,3',4'-tetramethoxyflavone) sinensetin (5,6,7,3',4'-pentamethoxyflavone). Limocitrin occurs in the peel of lemon as limocitrin-3-0-glucoside, and can be produced from the 3-glycoside by enzymatic and acid hydrolysis or by a chemical synthesis procedure. Two limocitrin analogues, limocitrin 3,7,4'-trimethylether and limocitrin-3,5,6-4' 20 tetramethylether, also occur in orange peel. Several polymethoxyflavones were tested and found to be active as inhibitors of apolipoprotein B (apoB) production and had negligible cytotoxicity in the human liver carcinoma cell line HepG2. It has been shown that humans with coronary heart disease (CAD) have higher levels of apoB in their blood. ApoB concentrations also reflect the number of LDL, and VLDL (very low density lipoprotein) 25 particles in arteries. Administering polymethoxylatedflavone of the invention to a mammal results in a reduction in the amount of substances in the blood which contribute to CAD, such as for example apoB, LDL, cholesterol, etc; preferably reduction of the serum, plasma, or whole blood concentration or in vivo amounts of these substances. Preferably, the concentration or in vivo amount of these substances is reduced to normal levels typically 30 found in such a mammal. Also, preferably, the polymethoxylatedflavone of the present invention are administered in amounts which produce little or no cytotoxicity, more preferably where no cytotoxicity is produced. By way of definition, a polymethoxylatedflavone is a flavone substituted with methoxy groups, preferably at least 2, more preferably at least 3, more preferably at least 4, more WO 2014/203059 PCT/IB2014/001069 6 preferably 4-8, and most preferably 4-7 methoxy groups and optionally substituted by one or more hydroxy groups, preferably 1-3, and more preferably 1-2 hydroxy groups. Four compounds of the present invention were synthesized from the lemon flavonoid limocitrin (3',8-dimethox-3,5,7,4'-tetrahydroxyflavone) for use in the present invention: 5 limocitrin-3,7,4'-trimethylether (5-hydroxy-3,7,8,3',4'-pentamethoxyflavone); limocitrin 3,5,7,4'-tetramethylether (3,5,7,8,3'4'-hexamethoxyflavone); and limocitrin-3,7,4' trimethylether-5-acetate. A number of methoxylated flavones, most of which occur naturally in citrus, have been found to be useful in the present invention. Also included are substituted derivatives of quercetin. 10 The compounds in these groups include 5-desmetlhymobiletin (5-hydroxy-6,7,8,3',4' pentamethoxyflavone); tetra-O-methylisoscutellarein (5,7,8,4'-tetramethoxyflavone); 3,5,6,7,8,3',4'-heptamethoxyflavone; nobiletin (5,6,7,8,3',4'-hexamethoxyflavone); tangeretin (5,6,7,8,4'-pentamethoxyflavone); sinensetin (5,6,7,3',4'-pentamethoxyflavone); 5 desmethylsinensetin (5-hydroxy-6,7,3',4'-tetramethoxyflavone); quercetin tetramethylether 15 (5-hydroxy-3,7,3',4'-tetramethoxyflavone); quercetin 3,5-dimethylether-7,3',4'-tribenzylether; quercetin pentamethyl ether (3,5,7,3',4'-pentamethoxyflavone); quercetin-5,7,3',4' tetramethylether-3 -acetate; quercetin-5,7,3',4'-tetramethylether (3-hydroxy-5,7,3',4' tetramethoxyflavone). Examples of tocotrienol compounds useful in the present invention include, but are not 20 limited to, are alpha-tocotrienol, gamma-tocotrienol, delta-tocotrienol, and mixtures thereof. The methods of the present invention may be administered to any mammal. Most preferably, the polymethoxylatedflavone useful in the methods of the present invention are administered to humans. In another aspect of the present invention, the polymethoxylatedflavone may be formulated 25 into a pharmaceutical preparation by a conventional method usually employed in the art. Dosages for the compositions of the present invention may be formulated into pharmaceutical preparations for administration to mammals. Many of the limocitrin derivatives, quercetin derivatives, naturally-occurring polymethoxyflavones, tocotrienol compounds and mixtures thereof may be provided as 30 compounds with pharmaceutically compatible counterions, a form in which they may be soluble. Counterions for the purposes of this invention include, for example, hydrophilic and hydrophobic agents. The polymethoxylatedflavone can be administered by a variety of routes, including oral, transdermal, rectal, intrarticular, intravenous, and intramuscular introduction. However, it WO 2014/203059 PCT/IB2014/001069 7 should be understood that the amount of the polymethoxylatedflavone actually administered ought to be determined in light of various relavent factors including the condition to be treated, the chosen route of administration, the age and weight of the individual patient, and the severity of the patient's condition, and therefore, the doses given herein should not be 5 construed to limit the scope of the invention in any way. The polymethoxylatedflavone useful in the present invention may be administered in a pharmaceutically or physiologically acceptable carrier. The pharmaceutically or physiologically acceptable carrier is any solvent with which the polymethoxylatedflavone is compatible and which is nontoxic to individuals treated at the amounts administered. A variety of delivery systems for pharmacological 10 compositions may be employed including, but not limited to, liposomes and emulsions. The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. 15 Formulations suitable for oral administration include liquid solutions of the active compound or compounds dissolved in a diluent such as, for example, saline, water, PEG 400; solid preparations such as capsules or tablets, each containing a predetermined amount of the active agent as solids, granules, gelatins, suspensions, and/or emulsions. Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic 20 sterile solutions which contain buffers, antioxidants, and preservatives. The formulations may be in unit dose or multi-dose containers. Dosages administered are any effective amount of a polymethoxylatedflavone which will, when given for the treatment, prophylactically or therapeutically, reduce or prevent cardiovascular diseases by reducing levels of substances which contribute to cardiovascular 25 diseases to normal or near normal levels in the blood or in vivo. By way of definition substances which contribute to cardiovascular diseases, include but are not limited to apoprotein B, low density lipoproteins, very low density lipoproteins, cholesterol, etc. For local administration, the composition can be administered by injection directly into a tissue, often in a depot or sustained release formulation. 30 Flavonoids Flavonoids are polyphenolic compounds that are found in plant foods, especially in oranges, grapefruits and tangerines. Polymethoxyflavones (PMFs) are flavonoid compounds having multiple methoxy substituents. Various beneficial effects of flavonoids are described in U.S. Pat. Nos. 6,251,400 and 6,239,114 and in PCT Publication Number WO 0 1/70029, the WO 2014/203059 PCT/IB2014/001069 8 disclosures of which are hereby incorporated by reference in their entireties. Other beneficial effects of flavonoid derivatives are discussed in U.S. Pat. Nos. 4,591,600; 5,855,892; and 6,096,364, the disclosures of which are also hereby incorporated by reference in their entireties. 5 The flavonoids present in citrus juices such as orange and grapefruit include, but are not limited to, hesperetin and naringenin respectively. Limonoids Limonoids are a group of chemically related triterpene derivatives found in the Rutaceae and Meliaceae families. Limonoids are among the bitter principles found in citrus fruits such as 10 lemons, lime, orange and grapefruit. They are also present as glucose derivatives in mature fruit tissues and seed, and are one of the major secondary metabolites present in citrus. Citrus fruit tissues and byproducts ofjuice processing such as peels and molasses are sources of limonoid glucosides and citrus seed contain high concentrations of both limonoid aglycones and glucosides. Limonoid aglycones in the fruit tissues gradually disappear during 15 the late stages of fruit growth and maturation. Thirty-eight limonoid aglycones have been isolated from citrus. The limonoids are present in three different forms: the dilactone (I) is present as the open D-ring form (monolactone), the limonoate A-ring lactone (II) and the glucoside form (III). Only the monolactones and glucosides are present in fruit tissues. 20 Compound III is the predominant limonoid glucoside found in all juice samples. In orange juice it comprises 56% of the total limonoid glucosides present, while in grapefruit and lemon juices, it comprises an average of 63% to 66% respectively. Procedures for the extraction and isolation of both aglycones and glucosides have been established to obtain concentrated sources of various limonoids. 25 Tocotrienols are present in palm oil and are a form of vitamin E having an unsaturated side chain. They include, but are not limited to alpha-tocotrienol, gamma-tocotrienol or delta tocotrienol. Soy Protein Soy protein is a complete protein derived from soy beans. Soybean isoflavones for example, 30 genistein, which is a minor component of soy protein preparations may have cholesterol lowering effects. Recent studies suggest that soy protein and soy isoflavones, genistein and daidzein, might also be beneficial in insulin resistance and Type II diabetes.

WO 2014/203059 PCT/IB2014/001069 9 Citrus limonoids, citrus flavonoids, tocotrienols or soy proteins may be formulated into pharmaceutical preparations for administration to mammals for prevention and treatment of insulin resistance, cardiovascular disease, hypercholesterolemia or atherosclerosis. Many of the citrus limonoids, flavonoids, tocotrienols or soy proteins may be provided as 5 compounds with pharmaceutically compatible counterions, a form in which they may be soluble. Formulations containing the citrus limonoids, citrus flavonoids, tocotrienols and/or soy proteins of the present invention may be administered by any acceptable means including orally, transdermally, rectally, intravenously, intramuscularly, intraperitoneally, 10 subcutaneously, topically, by inhalation or any other means. The oral administration means is preferred. Formulations suitable for oral administration are commonly known and include liquid solutions of the active compounds dissolved in a diluent such as, for example, saline, water, PEG 400, etc. Solid forms of the compounds for oral administration include capsules or tablets, each comprising the active ingredients and commonly known adjuvants. The active 15 ingredients in the solid dosage form may be present in the form of solids, granules, gelatins, suspensions, and/or emulsions, as will be apparent to persons skilled in the art. The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and 20 polymers such as polyethylene glycols. Formulations suitable for parenteral administration include aqueous and non aqueous isotonic sterile solutions containing buffers, antioxidants, preservatives and any other known adjuvants. Useful solutions for oral or parenteral administration can be prepared by any of the methods 25 well known in the pharmaceutical art, described, for example, in Remington's Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990). Formulations for parenteral administration can also include glycocholate for buccal administration, methoxysalicylate for rectal administration, or citric acid for vaginal administration. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. 30 Suppositories for rectal administration also can be prepared by mixing the drug with a non irritating excipient such as cocoa butter, other glycerides, or other compositions which are solid at room temperature and liquid at body temperatures. Formulations also can include, for example, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, and hydrogenated naphthalenes. Formulations for direct administration can include glycerol and WO 2014/203059 PCT/IB2014/001069 10 other compositions of high viscosity. Other potentially useful parenteral carriers for these drugs include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration can contain as excipients, for example, lactose, or can be aqueous solutions containing, for example, 5 polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Retention enemas also can be used for rectal delivery. Formulations of the present invention suitable for oral administration can be in the form of: discrete units such as capsules, gelatin capsules, sachets, tablets, troches, or lozenges, each 10 containing a predetermined amount of the drug; a powder or granular composition; a solution or a suspension in an aqueous liquid or non-aqueous liquid; or an oil-in-water emulsion or a water-in-oil emulsion. The drug can also be administered in the form of a bolus, electuary or paste. A tablet can be made by compressing or molding the drug optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing, in a suitable 15 machine, the drug in a free-flowing form such as a powder or granules, optionally mixed by a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered drug and suitable carrier moistened with an inert liquid diluent. Oral compositions generally include an inert diluent or an edible carrier. For the purpose of 20 oral therapeutic administration, the active compound can be incorporated with excipients. Oral compositions prepared using a fluid carrier for use as a mouthwash include the compound in the fluid carrier and are applied orally and swished and expectorated or swallowed. Pharmaceutically compatible birding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can 25 contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, 30 or orange flavoring. Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, WO 2014/203059 PCT/IB2014/001069 11 N.J.) or phosphate buffered saline (PBS). It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene 5 glycol, and liquid polyetheylene glycol), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the 10 injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin. Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are 15 prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation include vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution 20 thereof. Formulations suitable for intra-articular administration can be in the form of a sterile aqueous preparation of the drug that can be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems can also be used to present the drug for both intra-articular and ophthalmic 25 administration. Formulations suitable for topical administration, including eye treatment, include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops. Formulations for topical administration to the skin surface can be prepared by dispersing the 30 drug with a dermatologically acceptable carrier such as a lotion, cream, ointment or soap. Particularly useful are carriers capable of forming a film or layer over the skin to localize application and inhibit removal. For topical administration to internal tissue surfaces, the agent can be dispersed in a liquid tissue adhesive or other substance known to enhance adsorption to a tissue surface. For example, hydroxypropylcellulose or fibrinogen/thrombin WO 2014/203059 PCT/IB2014/001069 12 solutions can be used to advantage. Alternatively, tissue-coating solutions, such as pectin containing formulations can be used. For inhalation treatments, inhalation of powder (self-propelling or spray formulations) dispensed with a spray can, a nebulizer, or an atomizer can be used. Such formulations can 5 be in the form of a fine powder for pulmonary administration from a powder inhalation device or self-propelling powder-dispensing formulations. In the case of self-propelling solution and spray formulations, the effect can be achieved either by choice of a valve having the desired spray characteristics (i.e., being capable of producing a spray having the desired particle size) or by incorporating the active ingredient as a suspended powder in controlled 10 particle size. For administration by inhalation, the compounds also can be delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Systemic administration also can be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be 15 permeated are used in the formulation. Such penetrants generally are known in the art, and include, for example, for transmucosal administration, detergents and bile salts. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds typically are formulated into ointments, salves, gels, or creams as generally known in the art. 20 The active compounds can be prepared with carriers that protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those 25 skilled in the art. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811. Oral or parenteral compositions can be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form refers to physically discrete units 30 suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations WO 2014/203059 PCT/IB2014/001069 13 inherent in the art of compounding such an active compound for the treatment of individuals. Furthermore, administration can be by periodic injections of a bolus, or can be made more continuous by intravenous, intramuscular or intraperitoneal administration from an external reservoir (e.g., an intravenous bag). 5 Where adhesion to a tissue surface is desired the composition can include the drug dispersed in a fibrinogen-thrombin composition or other bioadhesive. The compound then can be painted, sprayed or otherwise applied to the desired tissue surface. Alternatively, the drugs can be formulated for parenteral or oral administration to humans or other mammals, for example, in effective amounts, e.g., amounts that provide appropriate concentrations of the 10 drug to target tissue for a time sufficient to induce the desired effect. Patient dosages for oral administration of citrus limonoids range from 1-500 mg/day, commonly 1-100 mg/day, and typically from 1-100 mg/day. Stated in terms of patient body weight, usual dosages range from 0.0 1-10 mg/kg/day, commonly from 0.0 1-2.0 mg/kg/day, typically from 0.01 to 2.0 mg/kg/day. 15 Patient dosages for oral administration of citrus flavonoids range from 200-5000 mg/day, commonly 1000-2000 mg/day, and typically from 500-1500 mg/day. Stated in terms of patient body weight, usual dosages range from 15-70 mg/kg/day, commonly from 15-30 mg/kg/day, typically from 7-21 mg/kg/day. Patient dosages for oral administration of tocotrienols range from 1-1200 mg/day, commonly 20 1-100 mg/day, and typically from 1-60 mg/day. Stated in terms of patient body weight, usual dosages range from 0.01-20 mg/kg/day, commonly from 0.01-2.0 mg/kg/day, typically from 0.01 to 1/0 mg/kg/day. Patient dosages for oral administration of soy protein range from 1-500 g/day, commonly 25 250 g/day, and typically from 25-100 g/day. 25 In certain preferred embodiments, the composition comprises about 300 mg polymethoxyflavones, about 100 mg hesperidin, about 100 mg naringin, about 30 mg limonoids and about 10 mg tocotrienols. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are 30 provided herein for purposes of illustration only, and are not intended to limit the scope of the invention. The following examples illustrate the use of the invention for glycemic control. They are intended to further illustrate the invention and are not intended to limit the scope of the invention as defined by the claims.

WO 2014/203059 PCT/IB2014/001069 14 EXAMPLE Subjects Forty-nine subjects aged 18-75 years with fasting blood glucose levels between 5.2-15.4 mmol/L (95 to 280 mg/dl), HbA Ic level of <12% and BMI of 25 to 40 kg/m2 were recruited 5 through local advertisement and the clinic's electronic patient database. Subjects were permitted to be on prescribed medications for the control of diabetes and cardiovascular disease. Subjects were excluded for the following reasons: pregnant or breastfeeding, on medications affecting weight, use of insulin, history of heart disease, cancer, alcohol or drug abuse, participation in a clinical research trial within 30 days prior to randomization, had food 10 restrictions, allergies or intolerances to the investigational product. All study investigations were conducted in accordance with the Declaration of Helsinki and in compliance with ICH Guidelines for Good Clinical Practices. This study was reviewed and approved by Integrative Ethical Review Board (Austin, TX). All subjects provided written informed consent prior to any study procedures. 15 Study Protocol The study was a randomized, double blind, placebo-controlled, parallel study conducted at SIBR Research, Inc., West Bradenton, Florida, USA over a 24 week period, between June 2007 and October 2008. At screening, inclusion and exclusion criteria, medical history and concomitant medications 20 were reviewed. Heart rate, blood pressure, height, weight, hip and waist circumference were measured and BMI calculated. Fasting blood was collected for the determination of complete blood count, electrolytes (Na, K, Cl), kidney function (creatinine, creatinine kinase, protein), liver function (aspartate aminotransferase, alanine transaminase and bilirubin), glucose, HbAlc, and lipid profile (total cholesterol, HDL-C, LDL-C and triglycerides). Further, 25 female subjects provided a urine sample for pregnancy testing. At baseline and at all other visits blood pressure and heart rate were assessed, anthropometric measurements recorded, and BMI calculated. Fasting blood was collected for the determination of glucose, insulin and HbA Ic. An oral glucose tolerance test (OGTT), where subjects consumed a 100g glucose beverage over a 10 minute period, was conducted on all 30 subjects at baseline and after 12 and 24 weeks. Briefly, blood samples collected at 30, 60, 120, 180 and 240 minutes post-glucose consumption were analyzed for glucose and insulin. Fasting blood was also collected at weeks 12 and 24 for the determination of complete blood count, electrolytes (Na, K, Cl), kidney function (creatinine, creatinine kinase, protein), liver function (aspartate aminotransferase, alanine transaminase and bilirubin), glucose, HbAlc, WO 2014/203059 PCT/IB2014/001069 15 and lipid profile (total cholesterol, HDL-C, LDL-C and triglycerides). All assessments in blood were analyzed by a certified local laboratory. Subjects maintained a diary for the duration of the study period to record concomitant therapies and adverse events. The subject diary was reviewed at each study visit. 5 Randomization and Blinding Fifty subjects were eligible to participate in the study. Subjects were randomized in a 1:1 ratio to receive either a composition of an embodiment of the present invention or a placebo in five blocks of ten. Both products were encapsulated by Innovative Health Products, Largo, Florida. The test products were similar in shape, size, weight and color. 10 Product The composition of an embodiment of the present invention (a citrus bioflavonoid complex formulation, 525mg/capsule) and placebo (microcrystalline cellulose, 525mg/capsule) were encapsulated by Innovative Health Products, Largo, Florida. 15 Component Amount Assay (Polymethoxylated flavones By 71.84% HPLC) Nobiletin 58.28% Tangeretin 13.56% Synephrin 0.35% In general, amounts of components may include: assay (polymethoxylated flavones by HPLC) greater than or equal to approximately 62%, nobiletin greater than or equal to 49%, tangeretin greater than or equal to approximately 13%, and synephrin less than or equal to 20 approximately 0.5%. Subjects were instructed to take two capsules per day, one capsule in the morning and one in the evening, with food for 24 weeks. Unused products were returned at each study visit to calculate treatment compliance. Statistical Analysis 25 The intention-to-treat analysis included all subjects who were randomized into the study and who completed at least one post-baseline study visit. The completer's analysis included all subjects who completed all visits of the 6 month study.

WO 2014/203059 PCT/IB2014/001069 16 Data is presented as means with standard deviations for those subjects completing the 24 week study; group descriptive statistics were calculated for each study group, and statistical comparisons of glucose and HbA lc were performed using Analysis of Covariance (ANCOVA) adjusting for baseline values. Statistical comparisons for baseline 5 characteristics, lipid profiles, insulin response and measures of safety (hematology, blood chemistry, biometrics and vital signs) were performed using Analysis of Variance (ANOVA). Comparisons of area under the glucose and insulin concentration curves and maximum concentration (Cmax) were made using data that was log transformed prior to statistical comparisons, which is the preferred method for determination of area under the concentration 10 curve. Within group comparisons of fasting glucose and 2 hour post-prandial glucose were made using a t-test. Analysis of safety was based on all subjects randomized to either treatment and known to have taken at least one dose of test product. Subjects that did not meet the recommended goals for diabetes treatment (i.e. the reduction of vascular disease risk factors and diabetes control) were also reassessed after the 6 months of supplementation with 15 the composition of an embodiment of the present invention or placebo, and the number of subjects that had achieved the recommended goals were identified and categorized accordingly. RESULTS There were no differences in baseline characteristics of the 49 subjects randomized to 20 treatment (Table 1). Thirty four subjects completed the trial, and subject characteristics were similar between groups (Table 2). There were 16 withdrawals during the study, however the number of withdrawals was not significant between groups (P = 0.36). 14.3% of subjects achieved the recommended goal for HbAIc (<7%) after 12 weeks of supplementation in the composition of an embodiment of the present invention group 25 compared to 0% in the placebo group. 33.3% of the subjects on the composition of an embodiment of the present invention achieved an LDL-C 5100mg/dL while only 15.4% achieved the same goal when on placebo. 20.0% of subjects on the composition of an embodiment of the present invention achieved total cholesterol levels <200mg/dL compared to 12.5% in placebo. 83.3% of subjects on the composition of an embodiment of the present 30 invention achieved systolic blood pressure <130mmHg as compared to 60% of subjects on placebo (Table 3). Glucose tolerance tests at baseline, week 12 and week 24 demonstrated a peak in blood glucose at 120 minutes, with levels at 240 minutes remaining above fasting levels (0 minutes) (Figure la and Ib). Both groups showed a mean increase in AUC (0-240minutes) and Cmax WO 2014/203059 PCT/IB2014/001069 17 from baseline to weeks 12 and 24. There was no between group statistical significance in the maximum concentration (Cmax) of glucose or AUC(0-240minutes) at baseline, week 12 or week 24. The time to maximum concentration (Tmax) of serum glucose was significantly longer for subjects on the composition of an embodiment of the present invention as 5 compared to placebo at week 12 (P = 0.01). This difference was not sustained through week 24. Fasting glucose and 2-hour postprandial glucose levels increased from baseline to week 24 in subjects of both groups, but to a lesser extent in subjects on the composition of an embodiment of the present invention. The within group increase in fasting glucose of subjects on placebo showed a trend toward significance at week 12 (P=0.08) and reached statistical 10 significance at week 24 (P=0.05). Although the composition of an embodiment of the present invention group showed an increase from baseline to week 12 and week 24, the increases were not statistically significant (P=0.85 and P=0.67, respectively). A significant within group increase in 2 hour post-prandial glucose levels was seen in the placebo group from baseline to week 12 (P=0.05) and continued to trend toward significance at week 24 15 (P=0.07). The within group change in 2 hour post-prandial glucose from baseline to week 12 and baseline to week 24 was not statistically significant for subjects on the composition of an embodiment of the present invention (Table 4). In subjects completing the study that had all three of the following criteria: fasting glucose >l00mg/dL, 2 hour post-prandial glucose >I40mg/dL and HbAlc of>7%; the fasting blood 20 glucose and OGTT profiles at week 12 and 24 were higher than those at baseline for subjects on placebo. In the composition of an embodiment of the present invention group, OGTT excursions at week 12 and 24 remained similar to the baseline profile (Figure Ic and Id). Subjects on the composition of an embodiment of the present invention demonstrated higher fasting insulin levels at all time points from baseline to week 24 in comparison to placebo 25 (Table 4). After 24 weeks of supplementation, the four hour insulin curve showed a blunting of the curve, which was not seen in subjects on placebo (Figure 2a and 2b). Serum HbA I c levels did not differ significantly between the composition of an embodiment of the present invention and placebo groups. The lipid panel (total cholesterol, triglycerides, LDL-C and HDL-C) improved for subjects in the composition of an embodiment of the 30 present invention group when compared with the placebo group, with a decreased trend in total cholesterol and LDL-C, and an increasing trend in HDL-C levels observed from baseline to week 24. Subjects on placebo demonstrated increases in total cholesterol, triglycerides and LDL-C and a decrease in HDL-C from baseline to week 24, however, the differences between groups were not significant (Table 5).

WO 2014/203059 PCT/IB2014/001069 18 Biometric measures (weight, BMI, waist circumference, hip circumference and waist-to-hip ratio) were consistent across both groups from baseline to week 24. Vital signs (systolic blood pressure, diastolic blood pressure and heart rate) were not significantly different between the composition of an embodiment of the present invention group and placebo group 5 after 24 weeks of supplementation. Safety There were no significant differences between groups with respect to any hematology or clinical measures of safety including CBC, electrolytes, kidney and liver function markers, at any point during the study. A total of four adverse events were assessed by the investigator as 10 having a possible or probable relationship to treatment, 3 in the composition of an embodiment of the present invention group (diarrhea, N=2; indigestion, N=1) and 1 in the placebo group (nausea, N=1). These assessments were made while the study was still blinded. Test article was discontinued for the two subjects reporting diarrhea. 15 Table 1. Baseline characteristics of subjects in the intention-to-treat analysis Composition (N=22) Placebo (N=21) ________________ P Value ' [NJ Mean (SD) {N] Mean (SD) Age (years) [22] 57.8 (11.5) [21] 57.2 (8.1) 0.85 Gender {f/n (%)} Male 12/22 (54.5%) 12/21 (57.1%) 1.00i Female 11/22 (45.5%) 9/21 (42.9%) On Diabetic Medication (f/n 16/22 (72.7%) 16/21(76.2%) 1.00f Height (m) [22] 1.7 (0.1) [211 1.7 (0.1) 0.83 Weight (kg) [22] 101.6 (30.9) [21] 104.3 (20.7) 0.74 BMI (kg/m2) [22] 34.8 (7.3) [21] 35.8 (5.3) 0.60 Waist Circumference (cm) [22] 111.2 (18.5) [21] 113.7 (13.2) 0.61 Hip Circumference (cm) [221 117.8 (16.1) [21] 120.9 (15.0) 0.52 Waist to Hip Ratio [22] 0.95 (0.09) [21] 0.94 (0.08) 0.70 Statistical comparisons were performed using Analysis of Variance (ANOVA). Statistical comparisons were performed using Fisher's Exact Test.

WO 2014/203059 PCT/IB2014/001069 19 Table 2. Baseline characteristics of subjects on the composition of an embodiment of the present invention or placebo for 6 months completing the study Composition (N=15) Placebo (N=19) P Value [NJ Mean (SD) [N] Mean (SD) Age (years) [15] 58.5 (13.0) [19] 57.7 (7.7) 0.84 Gender {f/n (%)} Male 7/15 (46.7%) 10/19 (52.6%) 1.00t Female 8/15 (53.3%) On Diabetic Medication (f/n 12/15(80.0%) 14/19(73.7%) 1.00Y (%)} Height (m) [15] 1.7 (0.1) [19] 1.7 (0.1) 0.98 Weight (kg) [15] 99.3 (30.6) [19] 99.7 (12.0) 0.96 BMI (kg/m2) [15] 34.5 (7.8) [19] 35.1(4.4) 0.77 Waist Circumference (cm) [15] 109.2 (16.7) [19] 111.0 (9.7) 0.52 Hip Circumference (cm) [15] 117.5 (16.0) [19] 118.1 (10.3) 0.83 Waist to Hip Ratio [15] 0.93 (0.09) [19] 0.94 (0.08) 0.73 Statistical comparisons were performed using Analysis of Variance (ANOVA). I Statistical comparisons were performed using Fisher's Exact Test. 5 WO 2014/203059 PCT/IB2014/001069 20 Table 3. Subjects that did not meet the recommended goals for diabetes treatment were identified at baseline. These subjects were assessed after 6 months of supplementation with the composition of an embodiment of the present invention or placebo. The number of subjects that achieved goals for vascular disease risk factors and diabetes control were 5 identified after 6 months of supplementation with the composition of an embodiment of the present invention and were categorized accordingly. Composition (n=15) Placebo (n=19) Subjects Above Goals at Baseline Subjects Above Goals at Baseline (f/n (%)) {f/n (%)} OGTT 2h:5 140mg/dL 15/15 (100.0%) 18/19 (94.7%) LDL-c 5 100mg/dL 9/15 (60.0%) 13/19 (68.4%) HbAlc 5 7% 7/15 (46.7%) 4/19 (21.1%) Total Cholesterol 5 200mg/dL 5115 (33.3%) 8/19 (42.1%) Systolic BP 5 130 mmHg 6/15 (40.0%) 10/19 (52.6%) Subjects above goals at baseline who Subjects above goals at baseline who achieve goals at week 24 (f/n (%)} achieve goals at week 24 (f/n (%)} OGTT 2h 5 140mg/dL 1/15 (6.7%) 0/18 (0.0%) LDL-c < 100mg/dL 3/9 (33.3%) 2/13 (15.4%) HbAlc 5 7% 1/7 (14.3%) 0/4 (0.0%) Total Cholesterol:5 200mg/dL 1/5 (20.0%) 1/8(12.5%) Systolic BP 5 130 mmHg 5/6 (83.3%) 6/10 (60.0%) WO 2014/203059 PCT/IB2014/001069 21 Table 4. Fasting blood glucose levels and 2-hour post-prandial glucose at baseline and week 12 and 24 for subjects who were completers on the composition of an embodiment of the present invention or placebo Study group Composition (n=15) Placebo (n=19) P value' INJ Mean ± SD INI Mean * SD Fasting Glucose (mg/dL) Baseline(Week 0) [15] 151.5 18.3 [19] 143.0 46.2 Week 12 [15] 153.3 ± 36.8 [19] 167.4 69.5 0.23 Week 24 [15] 158.5 ± 54.0 [19] 165.5 * 68.9 0.46 [15] 1.8 ±36.9 [19] 24.4 +57.5 Change from baseline to Week 12 0.20 P=0.85 P=0.08 [15] 7.0 ± 62.2 [19] 22.5 ± 47.8 Change from baseline to Week 24 0.42 P=0.67 P=0.05 2 Hour Glucose (mg/dL) Baseline(Week 0) [151311.3 ± 69.8 [19] 296.9 94.1 Week 12 [15] 330.3 ± 86.2 [19] 329.7 ± 101.5 0.54 Week 24 [15] 328.8 ± 101.7 [19] 326.2 ± 103.7 0.63 [15] 19.1 ±37.6 [1 9] 32.7 ±69.0 Change from baseline to Week 12 0.50 P=0.07 P=0.05 [15] 17.5 ±63.1 [19] 29.3 ±66.2 Change from baseline to Week 24 0.60 P=0.30 P=0.07 Fasting Insulin (ulU/mL) Baseline [15] 14.5 (10.8) [19] 16.1 (18.0) 0.91 Week 12 [15] 19.1 (17.8) [19] 14.5 (12.9) 0.39 Week 24 [15] 16.7 (15.7) [19] 14.3 (14.5) 0.65 Between group statistical comparisons were performed using Analysis of Covariance (ANCOVA) adjusting for 5 baseline values. Within group statistical comparisons were performed using a t-test.

WO 2014/203059 PCT/IB2014/001069 22 Table 5. Serum lipid profile of subjects supplemented with the composition of an embodiment of the present invention or placebo at baseline, week 12 and week 24 during the 6 month study. The composition of an Placebo (N=19) embodiment of the present P-Value invention (N=15) [NJ Mean (SD) [N] Mean (SD) Total Cholesterol (mg/dL) Baseline [15] 182.7 (42.3) [19] 182.6 (50.0) 0.99 Week 12 [151 179.9 (39.0) [19] 189.3 (44.0) 0.52 Week 24 [15] 179.6 (36.4) [19] 202.4 (59.0) 0.20 Triglycerides (mg/dL) Baseline [15] 180.9 (125.0) [19] 166.9 (88.1) 0.70 Week 12 [15] 186.0 (104.4) [19] 201.5 (118.0) 0.69 Week 24 [15] 209.9 (130.3) [19] 294.0 (315.5) 0.34 LDL-c (mg/dL) Baseline [15] 111.7 (28.1) [19] 114.1 (37.4) 0.84 Week 12 [15] 111.6 (31.2) [19] 116.5 (37.3) 0.69 Week 24 [15] 105.2 (29.4) [19] 120.2 (41.8) 0.25 HDL-c (mg/dL) Baseline [15] 38.7 (9.6) [19] 40.8 (13.0) 0.60 Week 12 [15] 38.6 (9.5) [19] 40.3 (11.9) 0,65 Week 24 [15] 39.3 (12.0) [19] 38.8 (11.2) 0.90 Statistical comparisons were performed using Analysis of Variance (ANOVA). 5 Fasting blood glucose levels for subjects on placebo showed a 17% and 16% (P=0.05) increase from baseline to week 12 and week 14, respectively. However those on the composition of an embodiment of the present invention showed only a 1.2% and 5% increase from baseline at week 12 and week 24. Two hour post-prandial glucose levels followed a 10 similar trend with subjects on placebo showing an 11% (P=0.05) and 10% (P=0.07) increase from baseline at week 12 and week 24 respectively with those on the composition of an embodiment of the present invention showing smaller increases, of 6% at both week 12 and 24. A progressive shift occurs in the contribution of fasting and post-prandial hyperglycemia when patients progress from mild to moderate hyperglycemia. These results are in agreement 15 with those reported in the literature where fasting blood glucose is known to increase as diabetes progresses and worsens. The significant within group increase in fasting glucose and 2h post prandial glucose in the placebo group despite being on medication confirms that conventional therapies alone are inadequate in control of the progression of disease and that WO 2014/203059 PCT/IB2014/001069 23 the composition of an embodiment of the present invention when added to the treatment model worked to decrease the elevation of these important surrogate biomarkers. Analysis of diurnal glycemic profiles of non-insulin treated diabetics found that post prandial hyperglycemia excursions are a strong predictor of cardiovascular disease compared to 5 fasting glucose. Completers in both groups showed similar excursion in the OGTT curve from baseline to week 12 and 24 however those on the composition of an embodiment of the present invention showed excursions that stayed close to their baseline profiles at week 12 and 24. This was reflected by the significantly longer Tmax than those on placebo at week 12. Higher fasting insulin at all time points from baseline to week 24 in subjects on the 10 composition of an embodiment of the present invention supported the smaller increases in fasting glucose in this group of subjects compared to those in placebo. When comparing the FG and OGTT excursions of subjects that were not meeting all three diabetic targets at baseline (FG >100mg/dL, 2 hour post-prandial glucose >140mg/dL and HbAlc of >7%) the OGTT excursions at week 12 and 24 for subjects on placebo were higher supporting the 15 significantly higher FG and 2h PP glucose in this group. Subjects in the composition of an embodiment of the present invention group showed OGTT excursions at week 12 and 24 that remained similar to the excursions that were seen at baseline and are supported by the significantly longer Tmax, smaller increase in FG and 2h PP and higher levels of fasting insulin. It is apparent that conventional treatments alone are inadequate to control post 20 prandial glycemia and the resulting fluctuations in blood glucose. Furthermore, glycemic control rates are lowest for diabetic subjects also diagnosed with hypertension, hyperlipidemia and/or obesity. The completers analysis showed that subjects on the composition of an embodiment of the present invention had decreasing trends in total cholesterol (1.5%), LDL-C (5.8%) and 25 increasing trends in HDL-C (1.6%) while subjects on placebo showed an increase in total cholesterol (11%), LDL-C (5.3%) and a decrease in HDL-C (4.9%). The natural progression of the disease was evident in subjects on placebo in spite of receiving appropriate drug therapy for diabetes and associated co-morbidities. Most available glycemic control treatments have been used in combination to lower blood 30 glucose in type 2 diabetes. A rational selection for combined diabetes therapy would include therapies which lower glucose production, increase insulin levels and control cardiovascular risk. The current study suggests a role for the composition of an embodiment of the present invention in the management of type 2 diabetes and for decreasing surrogate risk biomarkers providing cardio protection in subjects in a wide age range on conventional therapy. It was WO 2014/203059 PCT/IB2014/001069 24 also demonstrated that the composition of an embodiment of the present invention worked synergistically with the subjects' medication to improve and achieve diabetic treatment goals. Although the foregoing description is directed to the preferred embodiments of the invention, it is noted that other variations and modifications will be apparent to those skilled in the art, 5 and may be made without departing from the spirit or scope of the invention. Moreover, features described in connection with one embodiment of the invention may be used in conjunction with other embodiments, even if not explicitly stated above.

Claims

1. A method comprising administering an effective amount of a composition to a subject diagnosed with diabetes, wherein the subject is currently taking one or more prescribed medications for control of diabetes but are not within one or more guidelines 5 consisting of: HbAlc < 7%; LDL-C 5 100 mg/dL; total cholesterol < 200 mg/dL; and systolic blood pressure 5 130 mmHg, wherein after a predetermined period of supplementation with the composition, the subject is within at least one of the one or more guidelines.

2. The method of claim 1, wherein the composition comprises at least one limonoid, at least one flavonoid and at least one tocotrienol. 10

3. The method of claim 2, wherein the composition comprises at least one polymethoxyflavone.

4. The method of claim 1, wherein the one or more prescribed medications are metformin.

5. The method of claim 1, wherein the subject is a human. 15

6. The method of claim 1, wherein the predetermined period of supplementation is at least 12 weeks.

7. The method of claim 6, wherein the predetermined period of supplementation is at least 24 weeks. 20